Rhinocort Aqua Articles
ViroPharma buys option to acquire Meritage Pharma
28 December 2011
AstraZeneca opts to buy out rights to certain products from US Merck & Co JV for $647 million
2 March 2010
AstraZeneca settles over transfer pricing in UK, agreeing to pay £505 million; GSK slumps on Avandia news
23 February 2010
US FDA calls for new safety controls on long-acting asthma drugs that could hit sales potential
19 February 2010
Teva returns to profit, as 4th quarter 2009 sales leap 33%
16 February 2010
Merck & Co’s new combo asthma drug expected to garner peak year sales of over $250 million
10 February 2010
AstraZeneca sees strong earnings and revenue growth in2009 but a slowdown in 4th qtr
28 January 2010
AstraZeneca beats consensus forecasts with 3rd quarter 2009 profits up 22% raises forecasts
29 October 2009
Astellas to co-promote AstraZeneca’s Symbicort in Japan
4 August 2009
Verus sues AZ for $1.3B over contract exit
28 May 2009
Court grants AstraZeneca temp injunction against Apotex
17 April 2009
FDA asks for more info on Symbicort in young
7 April 2009
Cosmo's 2008 profit jumps 5.2% to $12.9M
30 March 2009
Stock Commentary - Europe - week to Mar 16, 2009
23 March 2009
CyDex presents strong data for nasal sprays
23 March 2009
Symbicort ups small airway function; study
23 March 2009
Symbicort approved in USA for COPD
9 March 2009
AstraZeneca's net income slips 1.6% in 4th qtr as generic competition starts to bite
9 February 2009
MAP Pharma updates on two Ph III programs
19 January 2009
Topiagen/NicOx discontinue COPD drug
15 January 2009
MAP leaps on up to $900M deal with AZ
12 January 2009
Santarus licenses two Cosmo MMX drugs for USA
12 January 2009
FDA divided on safety of Serevent and Foradil ahead of panel meeting
15 December 2008
US motavizumab appro delayed by info request
8 December 2008
Stock Commentary - Europe - week to Nov 24, 2008
1 December 2008
AstraZeneca axes jobs, closes plants
1 December 2008
AstraZeneca does deal with Teva over generic Pulmicort
1 December 2008
AZ drops 11% as FDA clears Teva's Pulmicort
24 November 2008
FDA allows Teva's Pulmicort to AZ's protests
24 November 2008
AZ presents SHINE/SUN data at CHEST 2008
10 November 2008
OPKO gets rights to Teva's budesonide
13 October 2008
Symbicort sees similar safety to budesonide
1 September 2008
Cosmo's first-half 2008 results beat forecasts
11 August 2008
Morria Bio initiates Ph II MRX-4 trial
30 June 2008
AZ submits sNDA for Symbicot in pediatric asthma
9 June 2008
Barr confirms Entocort patent challenge
2 June 2008
EPO revokes a Symbicort patent
12 May 2008
AstraZeneca submits Symbicort sNDA to US FDA
5 May 2008
MAP0005 comparable FEV1 to Symbicort
14 April 2008
US FDA begins safety review of LABA asthma drugs
10 March 2008
Merck & Co sells JV products to AZ
10 March 2008
AstraZeneca's net profit falls 12% on restructing charges from MedImmune buy, lower Nexium sales
11 February 2008
Fostair launched in UK as cheaper than GSK/AZ asthma MDIs
28 January 2008
MAP initiates Ph III trial of asthma product
14 January 2008
Stock Commentary - Europe - week to October 22, 2007
29 October 2007
Symbicort patent blow for AstraZeneca
29 October 2007
Cosmo licenses Budesonide MMX to Ferring
15 October 2007
AstraZeneca buys Verus asthma program
1 October 2007
SkyePharma's 6-month loss reduced 11%
1 October 2007
Small number of combination drugs reaching the Japanese market
24 September 2007
USA's NIH updated asthma treatment guidelines welcomed by industry
10 September 2007
Stock Commentary - Europe - week to July 2, 2007
9 July 2007
CORRECTION: AstraZeneca's Symbicort
9 July 2007
AstraZeneca's Symbicort available in the USA
2 July 2007
SMC clears Symbicort SMART for asthma
18 June 2007
AstraZeneca launches Symbicort SMART in UK
4 June 2007
MAP Pharma closes $50M financing
2 April 2007
AstraZeneca's CEO reviews Japan ops
5 March 2007
AstraZeneca welcomes updated GINA guidelines
20 November 2006
AstraZeneca completes Symbicort SMART MRP
16 October 2006
AstraZeneca's Symbicort reduces exacerbations
11 September 2006
New data challenges asthma management paradigm
4 September 2006
Symbicort gets US OK for asthma maintenance
31 July 2006
AstraZeneca's Symbicort SMART OKed in Australia
24 July 2006
Symbicort plus beta 2 agonist shows promise in COPD
10 July 2006
Strong data for AstraZeneca's Symbicort
3 July 2006
NicOx partner Topigen starts Ph II with TPI-1020
29 May 2006
CRx-170 performs well in Ph II asthma study
24 April 2006
COPD market set to grow 9% a year to reach $12B by 2014
17 April 2006
AstraZeneca welcomes TORCH trial results
3 April 2006
AstraZeneca's 4th-qtr profit leaps 30% but firm admits thin pipeline
13 February 2006
AstraZeneca profit leaps 30% but firm admits thin pipeline
6 February 2006
Innovata secures L25M Duohaler asthma deal
19 December 2005
MAP and Elan extend resp drug R&D accord
8 August 2005
Astra Zeneca 2nd-qtr pretax profit leaps 67%
8 August 2005
AstraZeneca sees 2nd-qtr pretax profit leap 67%
1 August 2005
EPO: Astra's Symbicort patent still valid
23 May 2005
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
